GLP-1/GIP agonists are contraindicated in patients with a personal or family history of medullary thyroid cancer
Your provider decides the schedule based on your blood tests and symptoms
10.1016/j.neuron.2018.07.023 Neuron 273 ZhangG

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.

[26] Lower doses may be used in women at risk for OHSS
Patients are advised to avoid anti-inflammatory medications around the time of injections to allow the intended inflammatory-healing process to occur